The worldwide occurrence of prostate cancer makes it a prevalent disease among male populations, while prompt detection increases the success of medical interventions. Standard diagnostic instruments, such as PSA testing, along with biopsy procedures, exhibit several weaknesses in terms of sensitivity levels, specificity standards, and invasiveness. Electrochemical biosensors are establishing themselves as advanced tools for early detection of prostate cancer with high accuracy. The chapter examines electrochemical biosensors that detect prostate cancer, providing detailed assessments of their design, working principles, and current advancements. A thorough initiation of improved prostate cancer diagnostics needs to emphasize the chapter and then discuss electrochemical biosensing fundamentals while introducing specific cancer biomarkers, including PSA, PCA3, and exosome-based indicators. The article examines the combination of nanomaterials and functionalized electrodes with microfluidic platforms to enhance sensor outcomes. These biosensors have found practical clinical applications, as demonstrated by case studies that showcase their use in point-of-care testing and wearable healthcare products. The specific implementation of these biosensors faces remaining barriers, including achieving certification-level reliability standards and complying with regulatory requirements. The analysis concludes by presenting prospective developments, accompanied by detailed information on how biosensors can enhance prostate cancer diagnosis through immediate examination, as well as non-invasive and precise measurement technologies.